| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Cytosorbents Corporation (NASDAQ: CTSO)
CTSO Technical Analysis
2
| As on 9th Jun 2023 CTSO STOCK Price closed @ 3.33 and we RECOMMEND Buy for LONG-TERM with Stoploss of 2.51 & Strong Sell for SHORT-TERM with Stoploss of 3.82 we also expect STOCK to react on Following IMPORTANT LEVELS. |
CTSOSTOCK Price
| Open | 3.40 | Change | Price | % |
| High | 3.48 | 1 Day | -0.07 | -2.06 |
| Low | 3.06 | 1 Week | 0.36 | 12.12 |
| Close | 3.33 | 1 Month | 0.87 | 35.37 |
| Volume | 27900 | 1 Year | -0.95 | -22.20 |
| 52 Week High 4.45 | 52 Week Low 1.03 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| CTSO Daily Charts |
CTSO Intraday Charts |
Whats New @ Bazaartrend |
CTSO Free Analysis |
|
|
CTSO Important Levels Intraday
| RESISTANCE | 4.14 |
| RESISTANCE | 3.88 |
| RESISTANCE | 3.72 |
| RESISTANCE | 3.56 |
| SUPPORT | 3.10 |
| SUPPORT | 2.94 |
| SUPPORT | 2.78 |
| SUPPORT | 2.52 |
CTSO Forecast May 2024
| 4th UP Forecast | 5.08 |
| 3rd UP Forecast | 4.52 |
| 2nd UP Forecast | 4.17 |
| 1st UP Forecast | 3.83 |
| 1st DOWN Forecast | 2.83 |
| 2nd DOWN Forecast | 2.49 |
| 3rd DOWN Forecast | 2.14 |
| 4th DOWN Forecast | 1.58 |
CTSO Weekly Forecast
| 4th UP Forecast | 4.58 |
| 3rd UP Forecast | 4.18 |
| 2nd UP Forecast | 3.93 |
| 1st UP Forecast | 3.68 |
| 1st DOWN Forecast | 2.98 |
| 2nd DOWN Forecast | 2.73 |
| 3rd DOWN Forecast | 2.48 |
| 4th DOWN Forecast | 2.08 |
CTSO Forecast2024
| 4th UP Forecast | 10.19 |
| 3rd UP Forecast | 7.99 |
| 2nd UP Forecast | 6.63 |
| 1st UP Forecast | 5.27 |
| 1st DOWN Forecast | 1.39 |
| 2nd DOWN Forecast | 0.03 |
| 3rd DOWN Forecast | -1.33 |
| 4th DOWN Forecast | -3.53 |
Cytosorbents Corporation ( NASDAQ USA Symbol : CTSO )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
CTSO Business Profile
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of post-operative complications of cardiopulmonary bypass surgery, and maintaining or improving the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, a device to remove toxic chemicals from the blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is based in Monmouth Junction, New Jersey. Address: 7 Deer Park Drive, Monmouth Junction, NJ, United States, 08852
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service